Monogram Orthopaedics 11/8/2023 Earnings Report

Monogram Orthopaedics EPS Results

• Actual EPS: -$0.03
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Monogram Orthopaedics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Monogram Orthopaedics Announcement Details

• Date: 11/8/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Monogram Orthopaedics (NASDAQ:MGRM), traded on Nasdaq under the ticker MGRM, is a commercial-stage medical device company focused on developing and delivering personalized knee replacement solutions. The company’s mission centers on improving patient outcomes in knee arthroplasty by leveraging advanced design and manufacturing methods to tailor implants and instrumentation to each individual’s unique anatomy.

At the core of Monogram’s offering is the Monogram Knee System, which combines proprietary imaging software with additive manufacturing techniques to produce patient-specific implants and surgical instruments. Preoperative MRI or CT scans are used to create a three-dimensional model of the patient’s knee, allowing the system to optimize implant geometry, alignment guides, and cutting blocks. This customized approach aims to enhance implant fit, reduce surgical times, and potentially improve post-operative function and comfort.

Founded in 2018 and headquartered in Menlo Park, California, Monogram Orthopaedics has secured FDA 510(k) clearance for its partial knee replacement system and completed its first commercial cases in leading U.S. orthopedic centers. The company continues to expand its commercial footprint across the United States, with plans to pursue additional regulatory approvals and market entry in select international regions.